Evotec drops as 9M results disappoint

Evotec SE

05/11/2025 08:42

** Drug-maker Evotec EVTG.DE shares fall 9.2% after a "disappointing" set of 9M results, according to Oddo BHF analyst Stephan Wulf

** The company reported decline in sales and an operating loss

** The earnings reflect a challenging environment, particularly in the D&PD segment, says Stephan Wulf

** Evotec shares, already down 13.5% YTD, are on track for their worst day since July, despite signing a deal with Swiss Sandoz to sell its facility in Toulouse, worth potentially $650 million

** "Weak 9M results offset by positive Sandoz deal update," said RX Securities analysts

 (Reporting by Maria Rugamer)

 ((Maria.rugamer@thomsonreuters.com))